Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials
Authors:
- Daren K HeylandDaren K Heyland
- John MuscedereJMJohn Muscedere
- John DroverJDJohn Drover
- Xuran JiangXJXuran Jiang
- Andrew G DayADAndrew G Day
- the Canadian Critical Care Trials GroupTGthe Canadian Critical Care Trials Group
Open Access
- 18 March 2011
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , R98
Abstract
Introduction: Due to resource limitations, few critical care interventions have been rigorously evaluated with adequately powered randomized clinical trials (RCTs). There is a need to improve the efficiency of RCTs in critical care so that more definitive high quality RCTs can be completed with the available resources. The objective of this study was to validate and demonstrate the utility of a novel composite outcome measure, persistent organ dysfunction (POD) plus death, for clinical trials of critically ill patients. Methods: We performed a secondary analysis of a dataset from a prospective randomized trial involving 38 intensive care units (ICUs) in Canada, Europe, and the United States. We define POD as the persistence of organ dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome assessments time points. In 600 patients enrolled in a randomized trial of nutrition therapy and followed prospectively for six months, we evaluated the prevalence of POD and its association with outcome. Results: At 28 days, 2.3% of patients had circulatory failure, 13.7% had renal failure, 8.7% had respiratory failure, and 27.2% had died, for an overall prevalence of POD + death = 46.0%. Of survivors at Day 28, those with POD, compared to those without POD, had a higher mortality rate in the six-month follow-up period, had longer ICU and hospital stays, and a reduced quality of life at three months. Given these rates of POD + death and using a two-sided Chi-squared test at alpha = 0.05, we would require 616 patients per arm to detect a 25% relative risk reduction (RRR) in mortality, but only 286 per arm to detect the same RRR in POD + mortality. Conclusions: POD + death may be a valid composite outcome measure and compared to mortality endpoints, may reduce the sample size requirements of clinical trials of critically ill patients. Further validation in larger clinical trials is required.Keywords
This publication has 24 references indexed in Scilit:
- A prognostic model for one-year mortality in patients requiring prolonged mechanical ventilation*Critical Care Medicine, 2008
- Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trialsBMJ, 2007
- REducing Deaths due to OXidative Stress (The REDOXS© Study): rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patientsProceedings of the Nutrition Society, 2006
- The development of a comorbidity index with physical function as the outcomeJournal of Clinical Epidemiology, 2005
- Validity of composite end points in clinical trialsBMJ, 2005
- Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care unitsCritical Care Medicine, 1998
- Multiple Organ Dysfunction ScoreCritical Care Medicine, 1995
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- APACHE IICritical Care Medicine, 1985
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982